BRPI0819719A2 - Compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e peparações farmacêuticas contendo os mesmos como agente ativo - Google Patents

Compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e peparações farmacêuticas contendo os mesmos como agente ativo

Info

Publication number
BRPI0819719A2
BRPI0819719A2 BRPI0819719-9A BRPI0819719A BRPI0819719A2 BR PI0819719 A2 BRPI0819719 A2 BR PI0819719A2 BR PI0819719 A BRPI0819719 A BR PI0819719A BR PI0819719 A2 BRPI0819719 A2 BR PI0819719A2
Authority
BR
Brazil
Prior art keywords
pepparations
pharmaceutical
preparing
methods
active agent
Prior art date
Application number
BRPI0819719-9A
Other languages
English (en)
Inventor
Chang-Seok Lee
Hyeon Joo Yim
Kyoung-Hee Kim
Jaeick Lee
Sung-Hack Lee
Kyu Woong Lee
Hee Bong Lee
Wan Su Park
Changhee Min
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BRPI0819719A2 publication Critical patent/BRPI0819719A2/pt
Publication of BRPI0819719A8 publication Critical patent/BRPI0819719A8/pt
Publication of BRPI0819719B1 publication Critical patent/BRPI0819719B1/pt
Publication of BRPI0819719B8 publication Critical patent/BRPI0819719B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0819719A 2007-12-21 2008-12-19 compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo BRPI0819719B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070134887 2007-12-21
KR10-2007-0134887 2007-12-21
PCT/KR2008/007543 WO2009082134A2 (en) 2007-12-21 2008-12-19 Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent

Publications (4)

Publication Number Publication Date
BRPI0819719A2 true BRPI0819719A2 (pt) 2015-06-16
BRPI0819719A8 BRPI0819719A8 (pt) 2015-09-22
BRPI0819719B1 BRPI0819719B1 (pt) 2020-09-24
BRPI0819719B8 BRPI0819719B8 (pt) 2021-05-25

Family

ID=40801676

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819719A BRPI0819719B8 (pt) 2007-12-21 2008-12-19 compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo

Country Status (14)

Country Link
US (1) US8470836B2 (pt)
EP (1) EP2220086A4 (pt)
JP (1) JP5358585B2 (pt)
KR (1) KR101105607B1 (pt)
CN (1) CN101903386B (pt)
AU (1) AU2008341352B2 (pt)
BR (1) BRPI0819719B8 (pt)
CA (1) CA2710109C (pt)
CO (1) CO6300861A2 (pt)
EA (1) EA201070635A1 (pt)
MA (1) MA31919B1 (pt)
UA (1) UA103181C2 (pt)
WO (1) WO2009082134A2 (pt)
ZA (1) ZA201004214B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MY157423A (en) * 2010-09-03 2016-06-15 Lg Life Sciences Ltd Production method of intermediate compound for synthesizing medicament
CN102617566B (zh) * 2011-01-30 2015-03-04 山东轩竹医药科技有限公司 吡啶并咪唑烷衍生物
CN102875567B (zh) * 2011-07-15 2015-03-11 天津药物研究院 一类含哌嗪化合物、制备及用途
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR101539761B1 (ko) * 2012-02-03 2015-07-28 주식회사 엘지생명과학 물 또는 다양한 산을 첨가제로 이용한 새로운 마이클-첨가 반응을 통하여 화합물을 제조하는 방법
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
CN105017244A (zh) * 2014-04-16 2015-11-04 上海药明康德新药开发有限公司 顺反叔丁基-4-氧六氢化-1H-吡咯[3,4-c]吡啶-2(3H)-羧酸叔丁酯的合成方法
CN104447511A (zh) * 2014-11-12 2015-03-25 江苏中邦制药有限公司 一种n-叔丁氧羰基-3-哌啶酮的合成方法
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
RU2741389C1 (ru) * 2017-11-16 2021-01-25 ЭлДжи КЕМ, ЛТД. Способ получения промежуточного соединения для синтеза лекарственного средства
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
CN118791425A (zh) * 2024-06-18 2024-10-18 浙江尚科生物医药有限公司 一种1-boc-3-哌啶酮及其类似环酮类化合物的合成方法
CN120004890B (zh) * 2025-02-17 2025-10-21 安徽峆一药业股份有限公司 一种吉格列汀盐酸盐微晶及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
EP1490335B1 (en) * 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2512546A1 (en) * 2003-01-17 2004-08-05 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004089362A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S 2-cyanopyrroles and their analogues as ddp-iv inhibitors
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
BRPI0819719A8 (pt) 2015-09-22
JP5358585B2 (ja) 2013-12-04
US8470836B2 (en) 2013-06-25
JP2011507832A (ja) 2011-03-10
BRPI0819719B8 (pt) 2021-05-25
CA2710109A1 (en) 2009-07-02
WO2009082134A3 (en) 2009-09-24
WO2009082134A2 (en) 2009-07-02
BRPI0819719B1 (pt) 2020-09-24
UA103181C2 (ru) 2013-09-25
EA201070635A1 (ru) 2010-12-30
CO6300861A2 (es) 2011-07-21
AU2008341352A1 (en) 2009-07-02
KR101105607B1 (ko) 2012-01-18
AU2008341352B2 (en) 2013-08-01
US20100274013A1 (en) 2010-10-28
KR20090068156A (ko) 2009-06-25
ZA201004214B (en) 2011-04-28
CN101903386B (zh) 2015-04-22
EP2220086A4 (en) 2010-12-22
EP2220086A2 (en) 2010-08-25
CA2710109C (en) 2016-07-19
MA31919B1 (fr) 2010-12-01
CN101903386A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
BRPI0819719A8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
PH12017501306A1 (en) Inhibitors of histone demethylases
LT3360575T (lt) Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
CO6741228A2 (es) Inhibidores de la neprilisina
TWI562992B (en) Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
BRPI0815606A2 (pt) Derivados de 6-triazol piridazina - sulfanil benzotiazol e benzimidazol, o respectivo processo de preparo, a respectiva aplicação a título de medicamentos, composições farmacêuticas e utilização, notadamente como inibidores de met.
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
BRPI1012129A2 (pt) enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
BRPI0914927A2 (pt) composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0922619A2 (pt) compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento
EP2286814A4 (en) TRANSDERMALE PREPARATION WITH PALONOSETRON
ME02017B (me) Jedinjenja, kompozicije i postupci za tretman beta-amiloidnih bolesti i sinukleinopatija
ITTO20110630A1 (it) Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
BRPI0908168A2 (pt) composto, medicamento, inibidor de dipeptidil peptidase-iv, agente terapêutico para diabetes, e, método de tratamento de diabetes
CL2015000110A1 (es) Metodo de prevencion o tratamiento de una respuesta farmacodinamica adversa inducida por opioides; unidad de dosis farmaceutica que comprende buprenorfina y otro opioide; kit farmaceutico. (divisional de la solicitud n°2790-2014).
BRPI1007334A2 (pt) composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD. (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF